The study shows MB-FUS can safely open the blood-brain barrier but doesn't explain why treatments were limited to first 3 days of each cycle or how long the opening persists. Understanding optimal dosing schedules could maximize drug delivery while minimizing repeated procedures. Gap type: open_question Source paper: Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. (2025, The Lancet. Oncology, PMID:41308679)
Landscape Summary: What mechanisms determine optimal timing and frequency of MB-FUS treatments for sustained BBB opening? is a 0.83 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What mechanisms determine optimal timing and frequency of MB-FUS treatments for sustained BBB opening? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: